Sinopharm Group reports Q3 net profit up 9.7% to 596M yuan

The divergence between the quarter and the nine-month picture is the real signal here: profit growth in Q3 contrasts with a year-to-date decline, suggesting the bottom line has only recently turned. Revenue growth is barely positive, so the profit improvement looks driven more by cost or margin factors than by demand — a distinction that matters for anyone tracking the wider pharma distribution chain. Whether the quarterly trend holds into the fourth quarter is the open question.